328 related articles for article (PubMed ID: 26978327)
1. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.
Aman MG; Findling RL; Hardan AY; Hendren RL; Melmed RD; Kehinde-Nelson O; Hsu HA; Trugman JM; Palmer RH; Graham SM; Gage AT; Perhach JL; Katz E
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):403-412. PubMed ID: 26978327
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.
Hardan AY; Hendren RL; Aman MG; Robb A; Melmed RD; Andersen KA; Luchini R; Rahman R; Ali S; Jia XD; Mallick M; Lateiner JE; Palmer RH; Graham SM
Autism; 2019 Nov; 23(8):2096-2111. PubMed ID: 31027422
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
4. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
[TBL] [Abstract][Full Text] [Related]
6. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
Ott BR; Blake LM; Kagan E; Resnick M;
J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
8. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder.
Joshi G; Wozniak J; Faraone SV; Fried R; Chan J; Furtak S; Grimsley E; Conroy K; Kilcullen JR; Woodworth KY; Biederman J
J Clin Psychopharmacol; 2016 Jun; 36(3):262-71. PubMed ID: 27043118
[TBL] [Abstract][Full Text] [Related]
10. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Hajizadeh-Zaker R; Ghajar A; Mesgarpour B; Afarideh M; Mohammadi MR; Akhondzadeh S
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):74-81. PubMed ID: 29027815
[TBL] [Abstract][Full Text] [Related]
11. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
12. Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial.
Leeman-Markowski BA; Meador KJ; Moo LR; Cole AJ; Hoch DB; Garcia E; Schachter SC
Epilepsy Behav; 2018 Nov; 88():315-324. PubMed ID: 30449328
[TBL] [Abstract][Full Text] [Related]
13. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.
Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Grigg J; Tan R; Cheng J; Arnold A; Gurvich C
CNS Drugs; 2018 Feb; 32(2):179-187. PubMed ID: 29549516
[TBL] [Abstract][Full Text] [Related]
15. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
17. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
18. Acute and long-term safety and tolerability of risperidone in children with autism.
Aman MG; Arnold LE; McDougle CJ; Vitiello B; Scahill L; Davies M; McCracken JT; Tierney E; Nash PL; Posey DJ; Chuang S; Martin A; Shah B; Gonzalez NM; Swiezy NB; Ritz L; Koenig K; McGough J; Ghuman JK; Lindsay RL
J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):869-84. PubMed ID: 16379507
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Lieberman JA; Papadakis K; Csernansky J; Litman R; Volavka J; Jia XD; Gage A;
Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
[TBL] [Abstract][Full Text] [Related]
20. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Bakchine S; Loft H
J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
